- Darolutamide Plus ADT Yields Significant OS Benefit in mHSPCDarolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.onclive · 2mo ago↗ source
- OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.onclive · 2mo ago↗ source
- Pembrolizumab Plus BCG Elicits 92% CR Rate in BCG-Naive Very High-Risk T1 NMIBCPembrolizumab plus BCG achieved a 92% 6-month complete response rate in very high-risk T1 bladder cancer with no progression to muscle-invasive disease.onclive · 2mo ago↗ source